Low postoperative lymphocyte count increases risk of progression in human papillomavirus associated oropharyngeal cancer

Background We aim to explore the prognostic role of absolute lymphocyte count (ALC) before, during, and after treatment on oncologic outcomes in human papillomavirus associated oropharyngeal cancer (HPV(+)OPSCC). Methods Retrospective cohort at a tertiary center, 2006–2018. Multivariable Cox regress...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Head & neck 2022-12, Vol.44 (12), p.2760-2768
Hauptverfasser: Yin, Linda X., Routman, David M., Day, Courtney N., Harmsen, William S., Haller, Travis, Bartemes, Kathleen, Price, Daniel L., Moore, Eric J., Foote, Robert L., Neben‐Wittich, Michelle, Chintakuntlawar, Ashish V., Ma, Daniel J., Price, Katharine A., Van Abel, Kathryn M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background We aim to explore the prognostic role of absolute lymphocyte count (ALC) before, during, and after treatment on oncologic outcomes in human papillomavirus associated oropharyngeal cancer (HPV(+)OPSCC). Methods Retrospective cohort at a tertiary center, 2006–2018. Multivariable Cox regressions were used to determine the effect of ALC on risk of progression. Univariate linear regression was performed to determine clinical factors associated with lower ALC. Results All 197 patients underwent primary surgery. Mean (SD) ALC nadirs (×109 cells/L) were: baseline (N = 149): 1.69 (0.56); postoperative (N = 126): 1.58 (0.59); post‐RT (N = 141): 0.68 (0.35) and long‐term (N = 105): 0.88 (0.37). Lower baseline ALC nadir was associated with worse overall survival (HR 3.85, 95%CI: 1.03–14.29, p = 0.04). Lower postoperative ALC nadir was associated with higher risk of progression (HR 2.63, 95%CI: 1.04–6.67, p = 0.04). Conclusions Lower baseline ALC is associated with worse survival, whereas lower postoperative ALC is associated with increased risk of progression in surgically treated HPV(+)OPSCC. Level of Evidence 3
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.27198